Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
deals
fda
3
×
life sciences
national blog main
national top stories
roche
clinical trials
genentech
san francisco blog main
alexion pharmaceuticals
alnylam pharmaceuticals
avapritinib
blueprint medicines
boehringer ingelheim
cancer
cancer immunotherapy
center for medicare and medicaid services
companion diagnostic
cstone pharmaceuticals
daniel o'day
dicerna pharamceuticals
eli lilly
european medicines agency
fisogatinib
flatiron health
foundation medicine
foundationone cdx
foundationone heme
hepatitis b
hepatitis b virus
hepatocellular carcinoma
hereditary transthyretin amyloidosis
investing
jeff albers
medullary thyroid cancer
new york blog main
What
roche
3
×
drug
medicines
pay
team
acquire
agreed
approval
big
billion
blueprint
broad
cancer
candidate
caught
causing
confidence
currently
dicerna
didn’t
disease
eye
fda
foundation
gain
gene
genentech
hepatitis
intended
marketing
medicine
momentum
morning
muscle
pact
panels
pays
pharma
pharmaceuticals
picked
Language
unset
Current search:
roche
×
boston
×
fda
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine